Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon Dec 11 | 2020Xeris Recieves Positive CHMP Opinion; Roche and Diabeloop Partner for AID DevelopmentPurchase Blast
$599
Posted in: Bolus Insulin, Other Dec 10 | 2020Novo Partners with Procyon Technologies for T1DM Stem-Cell Treatment; Bigfoot Expands Commercial Leadership Team; JDRF and Provention Bio Launch T1DM Screening Campaign; New Arecor Trial for Ultra-concentrated RAI; City of Hope Initiates Ph1 T1DM Vaccine TrialPurchase Blast
$599
Posted in: Glucose Monitoring Dec 10 | 2020Lifescan Redacts New CGM's Latest Trial RecordPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 09 | 2020Lilly Ph3 Tirzepatide SUPRASS-1 Data Lives up to Ph2b HypePurchase Blast
$599
Posted in: DPP-IVi, GLP-1RA Dec 07 | 2020Thoughts on Pediatric Exclusivity for Saxenda and JanuviaPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon Dec 07 | 2020Biocon/Mylan Bs-Aspart and Xeris Glucagon up for CHMP Opinions? CHMP Agenda December 7-10Purchase Blast
$599
Posted in: Basal Insulin Dec 07 | 2020Novo Retracts CONCLUDE (H2H Tresiba vs. Toujeo) Press ReleasePurchase Blast$599
Posted in: GLP-1RA Dec 04 | 2020Novo Files Sema 2.4mg Obesity Indication with FDAPurchase Blast
$599
Posted in: Glucose Monitoring Dec 03 | 2020Libre 2 Appears to Remain in US Soft Launch; When will Broad Launch Commence?Purchase Blast
$599
Posted in: Other Nov 30 | 2020Pharmaceutical Strategies Group Launches "Total Cost of Diabetes Care" Feature for Health Plans and EmployersPurchase Blast
$599
Posted in: Other Nov 24 | 2020Summary of Novartis Meet the Management Investor EventPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery Nov 24 | 2020Medtronic CY Q3 ’20 (FY Q2 ’21) Earnings Update; Dario Signs New Deal with Fortune 500 Company; Oramed Screens First Patients in the Ph3 ORMD-0801 TrialPurchase Blast
$599
Posted in: Other Nov 23 | 2020Amgen Returns Omecamtiv Rights to Cytokinetics; Risk-reward for CYTK Hinges on FDA AdcomPurchase Blast
$599
Posted in: Other Nov 20 | 2020Imeglimin Ph3 US and EU Development Discontinued by Metavant; Poxel Seeks Other OptionsPurchase Blast
$599
Posted in: Insulin Delivery Nov 19 | 2020Lilly Partners with Ypsomed for AID System; Tidepool Lays Off 40% of StaffPurchase Blast